Brief: Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation For TMB-001 For The Treatment Of Congenital Ichthyosis
31/05/2022 14:39
May 31 (Reuters) - Timber Pharmaceuticals Inc TMBR.A :
* TIMBER PHARMACEUTICALS RECEIVES FDA BREAKTHROUGH THERAPY
DESIGNATION FOR TMB-001 FOR THE TREATMENT OF CONGENITAL
ICHTHYOSIS
* TIMBER PHARMACEUTICALS INC - COMPANY PREPARING TO DOSE
FIRST
PATIENTS IN PIVOTAL PHASE 3 ASCEND CLINICAL TRIAL
Source text for Eikon: ID:nGNX1WjTlF
Further company coverage: TMBR.A
Recent news on Trex Wind-Down
See all newsBrief: NYSE American To Suspend Trading Immediately In Timber Pharma
Brief: Timber Pharmaceuticals Receives Court Approval Of All “First Day” Motions To Support Business
Brief: NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals
Brief: Timber Pharmaceuticals Says Prior To Filing Of Chapter 11 Case, Debtors Entered Into A "Stalking Horse" Asset Purchase Agreement
Brief: Timber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy - Court Filing